A carregar...
MicroRNA-506-3p increases the response to PARP inhibitors and cisplatin by targeting EZH2/β-catenin in serous ovarian cancers
Chemo-resistance is an important barrier to effective treatment of ovarian cancer. Poly (ADP-ribose) polymerase (PARP) inhibitors are currently promising targeted drugs used to treat BRCA-mutant ovarian cancer. Ovarian cancer patients with BRCA 1/2 mutations appear to benefit better from PARP inhibi...
Na minha lista:
| Publicado no: | Transl Oncol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Neoplasia Press
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7770486/ https://ncbi.nlm.nih.gov/pubmed/33360300 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2020.100987 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|